TT vs ZYME · P/E 36, rev $21.32B vs rev $76.3M
Trane Technologies plc (TT) versus Zymeworks Inc. Common Stock (ZYME) — a side-by-side from cached financials, not a winner call.
Trane Technologies plc (TT) is a building products & equipment company listed on NYSE.
Zymeworks Inc. Common Stock (ZYME) is a biotechnology company listed on NASDAQ.
Latest reported TT revenue for 2025-12-31 was $21.32B. Net income was $2.92B. Revenue was up 7.5% from 2024-12-31 to 2025-12-31. TT currently screens at market cap $104.45B and trailing P/E 36.2.
Latest reported ZYME revenue for 2024-12-31 was $76.3M. Net income was -$122.7M. Revenue was up 0.4% from 2023-12-31 to 2024-12-31. ZYME currently screens at market cap $1.68B.
TT currently screens at market cap $104.45B and trailing P/E 36.2. ZYME currently screens at market cap $1.68B.
Not investment advice. Open the TT and ZYME stock pages for the full models.
Not investment advice.